ALGS - Aligos Therapeutics, Inc.
Previous close
41.55
-0.170 -0.409%
Share volume: 2,934
Last Updated: Fri 27 Dec 2024 08:21:50 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$41.72
-0.17
-0.41%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-02 | 2023-03-09 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-03-12 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 182.523 M | 164.069 M | 146.693 M | 121.738 M | 106.130 M | 85.852 M | 151.527 M | 127.902 M | |
| Current Assets | 167.685 M | 150.093 M | 133.545 M | 109.429 M | 94.243 M | 74.643 M | 141.084 M | 118.064 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 8.320 M | 7.709 M | 7.603 M | 5.516 M | 3.363 M | 4.140 M | 5.310 M | 5.109 M | |
| Short Term Investments | 8.320 M | 7.709 M | 7.603 M | 5.516 M | 3.363 M | 4.140 M | 5.310 M | 5.109 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 159.344 M | 142.304 M | 125.827 M | 103.516 M | 90.838 M | 70.429 M | 135.704 M | 112.739 M | |
| Total Non-current Assets | 14.838 M | 13.976 M | 13.148 M | 12.309 M | 11.887 M | 11.209 M | 10.443 M | 9.838 M | |
| Property Plant Equipment | 5.781 M | 5.250 M | 4.816 M | 4.369 M | 3.951 M | 3.646 M | 3.259 M | 3.046 M | |
| Other Assets | 9.057 M | 8.726 M | 8.332 M | 7.940 M | 7.936 M | 7.563 M | 7.184 M | 6.792 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 182.523 M | 164.069 M | 146.693 M | 121.738 M | 106.130 M | 85.852 M | 151.527 M | 127.902 M | |
| Total liabilities | 45.542 M | 42.056 M | 42.793 M | 36.988 M | 36.495 M | 31.031 M | 59.447 M | 68.106 M | |
| Total current liabilities | 31.653 M | 30.541 M | 33.129 M | 28.079 M | 27.225 M | 22.468 M | 23.906 M | 18.880 M | |
| Accounts Payable | 2.762 M | 2.931 M | 4.737 M | 2.822 M | 3.241 M | 2.941 M | 2.517 M | 2.842 M | |
| Other liabilities | 3.386 M | 1.689 M | 233.000 K | 93.000 K | 93.000 K | 46.000 K | 27.642 M | 42.015 M | |
| Current long term debt | 2.934 M | 3.207 M | 3.143 M | 3.149 M | 3.237 M | 3.255 M | 3.239 M | 3.274 M | |
| Long term debt | 10.503 M | 9.826 M | 9.431 M | 8.816 M | 9.177 M | 8.517 M | 7.899 M | 7.211 M | |
| Other liabilities | 3.386 M | 1.689 M | 233.000 K | 93.000 K | 93.000 K | 46.000 K | 27.642 M | 42.015 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 136.981 M | 122.013 M | 103.900 M | 84.750 M | 69.635 M | 54.821 M | 92.080 M | 59.796 M | |
| Common stock | 42.666 M | 42.762 M | 42.842 M | 42.910 M | 43.215 M | 43.497 M | 127.420 M | 156.154 M | |
| Retained earnings | -358.611 M | -377.232 M | -399.118 M | -422.073 M | -440.864 M | -458.905 M | -486.797 M | -521.660 M |